Clinical use of relaxin to facilitate birth: reasons for investigating the premise.
In the United States, both medical and nonmedical factors have driven the cesarean section rate to over 26% of all deliveries. In addition to questions of increased cost associated with operative delivery, some have questioned the ethics of performing cesarean section for nonmedical reasons. Reduction of both the duration and the pain associated with vaginal delivery would likely bring about a decline in the rate of both medical and nonmedical cesarean sections. This chapter summarizes recent findings that support the premise that through its growth-promoting and softening effects on the cervix, short-term subcutaneous administration of pharmacologic amounts of relaxin to women at term holds promise as a means of reducing the duration and discomfort associated with delivery. Two recent studies conducted in pregnant rats demonstrated that the cervix is highly responsive to relaxin during the antepartum period and that short-term subcutaneous administration of the hormone to relaxin-deficient animals not only promotes growth and softening of the cervix, but also reduces the duration of labor and delivery. Moreover, recent human clinical trials examining the influence of 24 weeks of continuous subcutaneous administration of recombinant human relaxin for the treatment of scleroderma provided evidence not only that the human reproductive tract is responsive to relaxin, but also that the administration of the hormone does not cause serious adverse side effects. It is concluded that recent findings provide an impetus for an investigation into relaxin's potential for cervical remodeling and facilitating birth in women.
Lee
Hyung-Yul
HY
Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Zhao
Shuangping
S
Fields
P A
PA
Sherwood
O D
OD
D000818:Animals; D002584:Cervix Uteri / Q000187:drug effects / Q000502:physiology; D002585:Cesarean Section / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000494:pharmacology; D009929:Organ Size / Q000187:drug effects; D036801:Parturition / Q000187:drug effects*; D011247:Pregnancy; D012065:Relaxin / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*
D015735:Mifepristone; D012065:Relaxin